Homepage Top Section1

Selagine is a spin-out company from the University of Illinois at Chicago (UIC), while Grifols is a provider of plasma-derived medicines. A biologic drug, an immunoglobulin eye drop

Under the collaboration, both the companies will work together for further AI and machine learning-driven efforts in therapeutic development. The partnership aims to gather insights more precisely that

The once-daily oral medication FILSPARI has been designed to target two critical pathways selectively in the disease progression of IgAN (endothelin-1 and angiotensin II). It is said to

After granting priority review for the application, the FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of 5 August 2023. The drug is being evaluated

The optogenetic monotherapy has been developed to restore vision in blind patients. Nanoscope CEO Sulagna Bhattacharya said: “We are pleased to receive the FDA’s decision to grant Fast

Under the terms of the partnership deal between the companies, Hyloris will receive a share on any revenues related to product, such as royalties, license fees, milestone payments,

The recombinant adeno-associated virus (rAAV)-based gene therapy is being studied to treat neovascular Age Related Macular Degeneration (nAMD), which causes severe loss of vision and irreversible blindness across

The inhaled mRNA-based therapeutic is intended for people with CF, including those with genotypes that are not responsive to approved CFTR modulators. ReCode Therapeutics CEO Shehnaaz Suliman said:

As per the terms of the agreement, Spruce will get an upfront payment of $15m from Kaken. It will also be eligible to get further payments following the